骨髓增生异常综合征患者骨髓CD34＋CD38-CD123＋细胞内STAT5磷酸化水平变化  

STAT5 phosphorylation in CD34＋ CD38 - CD123＋ bone marrow cells of the patients with myelodys- plastic syndrome

作　　者：刘炳楠[1] 付蓉[1] 王化泉[1] 李丽娟[1] 岳兰竹[1] 阮二宝[1] 瞿文[1] 梁勇[1] 王国锦[1] 王晓明[1] 刘鸿[1] 吴玉红[1] 宋嘉[1] 邢莉民[1] 关晶[1] 王珺[1] 邵宗鸿[1] 

机构地区：[1]天津医科大学总医院血液肿瘤科,300052

出　　处：《中华血液学杂志》2012年第6期480-483,共4页Chinese Journal of Hematology

基　　金：国家自然科学基金（81170472、30971286、30971285）;高等学校博士学科点专项科研基金（200800620004）;天津市自然科学基金（08JCYBJC07800、09JCYBJC11200）;卫生部卫生行业科研专项（201002024）;天津医科大学重点学科基金（2009xk50、2009xk51）;天津市卫生行业重点攻关项目（11KG135）

摘　　要：目的研究骨髓增生异常综合征（MDS）患者骨髓CD34＋CD38-CD123＋细胞信号转导和转录活化蛋白5（STAT5）磷酸化（P-STAT5）水平，初步探讨MDS患者骨髓原代细胞胞内与增殖有关的STAT5存在状态。方法采用流式细胞术分别检测36例MDS患者及14名正常对照者原代骨髓单个核细胞（BMMNC）在给予10U／m1EPO刺激前后CD34＋CD38CD123＋和CD34＋CD38CD123-细胞P．STAT5表达水平[以平均荧光强度（MFI）表示]。结果未加入EPO刺激的高、低危组患者CD34＋CD38-CD123＋细胞P—STAT5表达水平分别为173．05±102．78和113．71±67．22，明显高于CD34＋CD38-CD123-细胞（68．99±50．42和58．84±27．51，P值分别〈0．01和〈0．05）和正常对照组CD34＋CD38-CD123-细胞（63．06±21．06，P值分别〈0．01和〈0．05），MDS患者组与正常对照组CD34＋CD38-CD123-细胞P，STAT5表达水平比较差异无统计学意义（P〉0．05）；EPO刺激的高、低危组患者CD34＋CD38CD123＋细胞P—STAT5表达水平分别为239．45-．I-152．05和144．04±58．11，明显高于CD34＋CD38-CD123-细胞（64．21±23．43和68．41±25．10，P值均〈0．01）和正常对照组CD34＋CD38-CD123-细胞（75．21±27．02，P〈0．01），MDS患者组与正常对照组CD34＋CD38-CD123-细胞P—STAT5表达水平比较差异无统计学意义（P〉0．05）。EPO刺激后，高、低危组患者CD34＋CD38-CD123＋细胞P—STAT5表达水平的中位增高值分别为28．86和21．80，明显高于CD34＋CD38-CD123-细胞（5．50和7．42，P值分别〈0．01和〈0．05）和正常对照组CD34＋CD38-CD123-细胞（6．39，P值分别〈0．01和〈0．05）；EPO刺激前后MDS患者组与正常对照组CD34＋CD38-CD123细胞P—STAT5表达的增高水平比较差异无统计学意义（P〉0．05）；EPO刺激前后CD34＋CD38-CD123＋细胞P—STAT5表达水平及刺激后增高水平在高、低危组患者问差异无统计学意义（P值均〉0．05）。结论MDS患者Objective To investigate the expressions of STAT5 phosphorylation in CD34 ＋CD38- CD123 ＋ bone marrow cells of the patients with myelodysplastic syndromes （MDS） , and then evaluate the lev- el of activation of STATS associated with cell proliferation in MDS elone cells. Methods The bone marrow mononuclear cells （BMMNC） were extracted from 36 MDS patients and 14 normal controls. The mean fluorescence intensities （MFI） of phosphorylated STAT5 （ P-STAT5 ） in CD34 ＋ CD38 - CD123 ＋ and CD34 ＋ CD38- CD123- cells, with or without the stimulation of 10 U/ml EPO, were examined by flow cytometry （FCM）. Results Without stimulation, the P-STAT5 MFI in CD34 ＋ CD38 - CD123 ＋ cells of low/high risk MDS patients was 113.71 ± 67.22/173.05 ± 102.78, which was significantly higher than that of CD34 ＋ CD38 - CD123 - cells （58.84 ±27.51/68.99 ± 50.42, P 〈 0.01, P 〈 0.05 ） and the normal controls CD34 ＋ CD38 - CD123 - cells （63.06 ±21.06, P 〈0. 05 ）, there was no significant difference between the CD34 ＋ CD38-CD123- cells of MDS patients and the normal control CD34＋ CD38- CD123- cells; With the EPO stimulation, the P-STAT5 MFI in CD34 ＋ CD38 - CD123 ＋ cells of low/high risk MDS patients was 144.04 ± 58.11/239.45± 152.05, which was significantly higher than that of CD34 ＋ CD38 - CD123 - cells （68.41 ± 25,10/64.21 ± 23.43, P 〈 0.01 ） and the normal controls CD34 ＋ CD38 - CD123 - cells （ 75.21 ± 27.02, P 〈0.01 ） , there was no significant difference between the CD34 ＋ CD38 - CD123 - cells of MDS patients and the normal control CD34 ＋ CD38 - CD123 - cells; The P-STAT5 MFI in the CD34＋ CD38- CD123 ＋ cells of low/high risk MDS patients with or without EPO stimulation were 21.80/28.86, which was significantly high- er than that of CD34 ＋ CD38 - CD123 - cells （7.42/5.50, P 〈 0.01, P 〈 0.05 ） and the normal controls CD34＋ CD38- CD123- cells （6.39, P 〈 0.05）, there was no significant difference between the CD34＋ CD38- CD123- cells of

关 键 词：骨髓增生异常综合征 肿瘤干细胞 红细胞生成素 重组 信号转导和转录活化蛋白 

分 类 号：R551.3[医药卫生—血液循环系统疾病]